GOSS

Gossamer Bio Inc

$0.17

93.12% · 1Y change

Trend

Bearish

-94.13%

P/E

—

Div yield

—

Mkt cap

$81.8M

Beta

2.01

Trend read · Bearish

How GOSS performs — and a starting point for your own research.

Price & mood

Market Mood

PriceEMA 12/39/233 (trend)Range 1Y $0.11 – $3.87

Idea: EMA

1Y Return

+41.9%

Sharpe 3Y

0.75

Market comparison

vs sector & industry

GOSS

1Y performance

-93.12%

Past performance. The future stays open.

Wall Street coverage

third-party context

Wall Street coverage

$1.66median target· current $0.17 (+858.9%)7 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-0.660.0% YoY

Profit margin-235.0%HEALTHCARE

Market cap$81.8MMicro cap

Valuation

Forward P/E: —
PEG ratio: —
P/B: 2.66
P/S (TTM): 1.54
EV/EBITDA: -0.39

Profitability & growth

ROE (TTM): -783.0%
Operating margin: -282.2%
Revenue growth YoY: -19.6%
Dividend yield: —
Beta: 2.01

Last earnings

Aug 4, 2026 · Estimate $-0.10 · Reported $-0.20

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Gossamer Bio Inc

Company profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapies in the areas of immunology, inflammation, and oncology diseases in the United States. The company is headquartered in San Diego, California.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 3115 MERRYFIELD ROW, SAN DIEGO, CA
Fiscal year end: December
Latest quarter: Jun 30, 2026

Market cap$81.8M

Shares outstanding$488.8M

52W high$3.87

52W low$0.11

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

GOSS

Price & mood

Market comparison

Wall Street coverage

Wall Street coverage

News & Sentiment

Gossamer Bio Amends Charter for New Preferred Financing

H.C. Wainwright reiterates Gossamer Bio stock rating on NDA progress

$Gossamer Bio (GOSS.US)$ they cant recover. 👩‍🚀🚀

Gossamer Bio (NASDAQ: GOSS) has 6% of its stock under D. E. Shaw’s reported influence

Gossamer Bio announces $250m in funding to advance seralutinib

Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones

Latham Advises Gossamer Bio on Structured Private Placement

Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval

Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Challenging Valuation Metrics

Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio Secures Up to $250M to Advance Seralutinib Toward FDA Approval

Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell

$Gossamer Bio (GOSS.US)$ @traderslink_this_guy@TradersLink__ we never lacking 🤷‍♂️ 😉

Gossamer Bio secures up to $250m in milestone-based financing

Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Revenue per share of Gossamer Bio, Inc. – HAM:4GB

Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib

Gossamer Bio: Q2 Earnings Snapshot

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Fundamentals

Valuation

Profitability & growth

About Gossamer Bio Inc

Classification

Company profile

GOSS

Price & mood

Market comparison

GOSS Market Analysis

GOSS

Price & mood

Market comparison

Wall Street coverage

Wall Street coverage

News & Sentiment

Gossamer Bio Amends Charter for New Preferred Financing

H.C. Wainwright reiterates Gossamer Bio stock rating on NDA progress

$Gossamer Bio (GOSS.US)$ they cant recover. 👩‍🚀🚀

Gossamer Bio (NASDAQ: GOSS) has 6% of its stock under D. E. Shaw’s reported influence

Gossamer Bio announces $250m in funding to advance seralutinib

Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones

Latham Advises Gossamer Bio on Structured Private Placement

Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval

Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Challenging Valuation Metrics

Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio Secures Up to $250M to Advance Seralutinib Toward FDA Approval

Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell

$Gossamer Bio (GOSS.US)$ @traderslink_this_guy@TradersLink__ we never lacking 🤷‍♂️ 😉

Gossamer Bio secures up to $250m in milestone-based financing

Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Revenue per share of Gossamer Bio, Inc. – HAM:4GB

Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib

Gossamer Bio: Q2 Earnings Snapshot

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Fundamentals

Valuation

Profitability & growth

About Gossamer Bio Inc

Classification

Company profile

GOSS

Price & mood

Market comparison